Rob Miani joined the MMRF team as Chief Financial Officer in 2016. Most recently he was the Vice President of Finance and Corporate Controller of Aptuit, LLC, a global contract research organization providing integrated early discovery to mid-phase drug development services in the pharmaceutical industry. Rob has over 20 years of leadership experience in the private and public sectors, holding managerial positions in the renewable energy, private equity, Internet and technology industries, including Davenport Newberry, Oak Investment Partners and INT Media Group. He began his career with Arthur Anderson LLP in the Assurance and Business Advisory Services Division. Rob is a CPA and received his BS degree in Accounting from Fairfield University.
Statement from the Multiple Myeloma Research Foundation Regarding the Precision Medicine Initiative
Statement from the Multiple Myeloma Research Foundation Regarding the Precision Medicine Initiative
“We applaud the President’s proposal to create a repository of genetic information from one million people, and believe it will accelerate the development of the next generation of treatments for a wide range of diseases,” said Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation.
Norwalk, Conn., Feb. 2, 2015 – The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the Precision Medicine Initiative, which was detailed by the President on Friday, January 30 at the White House.
“We applaud the President’s proposal to create a repository of genetic information from one million people, and believe it will accelerate the development of the next generation of treatments for a wide range of diseases,” said Walter M. Capone, President and Chief Executive Officer of the Multiple Myeloma Research Foundation.
“Increased understanding of the genomic basis of all cancers, including multiple myeloma, will help physicians to identify the right treatment options for patients in need, and help researchers design new ways of addressing cancer by targeting its molecular drivers.
“For more than eight years, the MMRF has worked with leaders from industry and academia to support the development of a precision medicine approach, by sequencing the myeloma genome and designing and launching the CoMMpass Study™, which tracks the outcomes and genomic profile of more than 1,000 participants. We make all data and findings publicly available on the MMRF Researcher Gateway in an effort to improve clinical care and accelerate the development of new targeted therapies.
“We offer our support to the federal government and welcome the opportunity to collaborate to advance this important initiative.”
About Multiple Myeloma (MM)
Multiple myeloma (MM) is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 24,050 adults (13,500 men and 10,550 women) in the United States will be diagnosed with MM in 2014 and an estimated 11,090 people are predicted to die from the disease. The five-year survival rate for MM is approximately 43%, versus 28% in 1998.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised $275 million since its inception and directs nearly 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.
